Physician profile
Robert Scott Fell
NPI 1396908067
$3,856.94
in general payments reported to CMS, 2019-2025
31 companies · $902 in 2025
The $902 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $115 · 2021: $85.33 · 2022: $84.70 · 2023: $747 · 2024: $1,258 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.12 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $454.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $437.30 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Abbvie INC. | $420.63 | 2023-2025 | |
| Amgen INC. | $363.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Shield Therapeutics INC | $343.93 | 2024-2025 | |
| Pfizer INC. | $159.05 | 2020-2025 | |
| Medtronic, INC. | $146.69 | 2025 | Interstim |
| Novartis Pharmaceuticals Corporation | $132.34 | 2019-2024 | |
| Dexcom, INC. | $94.49 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $94.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.36 | 2019-2025 | Jardiance |
| Abbott Laboratories | $86.59 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $70.41 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $58.78 | 2023-2024 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $53.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.05 | 2019 | |
| Merck Sharp & Dohme LLC | $38.53 | 2019-2020 | |
| Edwards Lifesciences Corporation | $24.06 | 2024 | Sapien 3 Ultra Resilia |
| Sanofi Pasteur INC. | $23.60 | 2019 | |
| Enterra Medical, INC. | $22.88 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.09 | 2024 | Gvoke Hypopen |
| Lifescan, INC. | $21.70 | 2023 | |
| Phadia US INC. | $19.73 | 2024 | Immunocap |
| Philips North America LLC | $17.80 | 2024 | (Ck6) Holter |
| Hikma Pharmaceuticals USA | $17.63 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.81 | 2019 | |
| Mylan Specialty L.P. | $13.75 | 2023 | Yupelri |
| Allergan, INC. | $13.54 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.